SCHEMBL21729515

SCHEMBL21729515

CC(C)[C@H](NC(=O)OC(C)(C)C)c1nc2cc(-c3cnoc3)sc2c(=O)[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 3/20 0.37
▸ CDC7 O00311 4/20 0.35
▸ DBF4 Q9UBU7 4/20 0.35
▸ ROCK1 Q13464 3/20 0.35
▸ RAB9A P51151 3/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ABCB1 P08183 4/20 0.33
▸ LMNA P02545 3/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CCNE1 P24864 2/20 0.32
▸ CDK2 P24941 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28458939 1.00 AAK1 (0.37) AAK1CDC7DBF4ROCK1RAB9A
SCHEMBL20570765 0.87 CDC7 (0.40) CDC7DBF4ROCK1RAB9AMEN1
SCHEMBL21729500 0.86 AAK1 (0.42) AAK1CDC7DBF4ROCK1RAB9A
SCHEMBL21729493 0.84 AAK1 (0.42) AAK1CDC7DBF4ROCK1RAB9A
SCHEMBL28453787 0.84 CDC7 (0.43) AAK1CDC7DBF4ROCK1RAB9A
SCHEMBL21729495 0.84 CDC7 (0.43) AAK1CDC7DBF4ROCK1RAB9A
SCHEMBL21729586 0.84 AAK1 (0.39) AAK1CDC7DBF4ROCK1RAB9A
SCHEMBL28457041 0.84 AAK1 (0.42) AAK1CDC7DBF4ROCK1RAB9A
SCHEMBL21729584 0.81 AAK1 (0.37) AAK1CDC7DBF4ROCK1RAB9A
SCHEMBL28446403 0.81 ABCB1 (0.37) AAK1MEN1KMT2AABCB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745410-B2 Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents ZENJI RESEARCH LABORATORIES (CN) 2020-08-18 — — US disclosed
US-20200055867-A1 SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS ZENJI RESEARCH LABORATORIES (CN) 2020-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055867-A1 SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS CDC7, CDK7, CDK17 AAK1 910/4885CDC7 1/4885DBF4 1421/4885
US-10745410-B2 Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents CDC7, CDK7, CDK17 AAK1 910/4885CDC7 1/4885DBF4 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback